STE.NYSESteris PLC

Form 4: STERIS Executive Equity Grant and Tax Withholding

Sentiment:

Statement of Changes in Beneficial Ownership


Senior VP and General Counsel John Adam Zangerle received equity grants and executed tax-related share withholdings.

Summary

  • John Adam Zangerle, Senior VP, General Counsel, and Secretary of STERIS plc, was granted 4,359 ordinary shares.
  • The executive also received an option to purchase 15,200 ordinary shares at an exercise price of $230.74.
  • 247 shares were withheld to satisfy tax obligations related to the vesting of restricted shares.
  • Following these transactions, the reporting person holds 37,444 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive compensation and does not signal a change in company strategy or financial health.

Positives

  • The executive's increased equity stake aligns personal interests with long-term shareholder value.
  • The grant of stock options provides incentive for future performance and retention.

Negatives

  • The transaction involved a tax-related withholding of shares, which is a standard administrative procedure but reduces the net share gain.

Risks

  • The value of the equity and options is subject to market volatility and the future performance of STERIS plc stock.

Future Outlook

The options vest in four equal annual installments starting June 2, 2027, through June 3, 2030, indicating a long-term retention strategy.

Management Comments

  • The transactions were executed in accordance with standard equity compensation plans and tax withholding requirements.

Industry Context

StockSavvy.ai notes that routine equity grants to C-suite executives are standard corporate governance practices intended to ensure management alignment with shareholder interests in the medical technology sector.

Comparison to Industry Standards

  • The use of restricted stock units and stock options is consistent with compensation structures at peer medical device companies like Medtronic and Boston Scientific.
  • Tax withholding via share reduction is a standard industry practice for settling tax liabilities upon the vesting of equity awards.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity CompensationGrant of restricted shares and stock options to the General Counsel.06/02/2026Standard alignment of executive compensation with long-term performance.

Stakeholder Impact

  • Shareholders: Minimal impact; reflects standard executive compensation practices.
  • Employees: No direct impact.

Next Steps

  • Vesting of restricted shares on June 3, 2026.
  • Commencement of option exercisability on June 2, 2027.

Key Dates

DateDescription
06/02/2026Transaction date for equity grants, tax withholding, and option issuance.
06/03/2026Lapse of restrictions on a portion of shares.
06/04/2026Filing date of the Form 4.
06/02/2027First vesting date for stock options.
06/02/2036Expiration date for the granted stock options.

Keywords

STERIS, STE, Form 4, Insider Trading, Equity Compensation, Stock Options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.